Bayer has made an investment of $250m (€236.78m) in a new manufacturing plant at Berkeley, California, US, to produce cell therapies for use across the globe.

Spread over 100,000ft², the Cell Therapy Launch Facility will aid in manufacturing material needed for clinical trials.

It will also manufacture material for the prospective commercial launch of bemdaneprocel (BRT-DA01).

An investigational cell therapy of Bayer’s subsidiary BlueRock Therapeutics, bemdaneprocel is currently being assessed for the treatment of Parkinson’s disease. 

The facility has modular space for cell culture, viral transduction and automated cell therapy filling.

With the expansion of Bayer’s portfolio, it will provide capacity for a second module of manufacturing suites to include more cell therapies. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The opening of the new facility is part of Bayer’s transformation strategy at the biotechnology site in Berkeley.

The company has made investments of $500m between 2018 and 2023.

Bayer Pharmaceuticals division president Stefan Oelrich stated: “This new facility ensures our investment in cell therapies can become a reality for patients around the world. 

“Cell therapies represent an important opportunity to treat diseases differently by targeting the underlying cause or enabling the human body to restore vital functions.”

The biotech team of Bayer offers its biologic development and production expertise for the company’s biotherapeutics portfolio.

The portfolio comprises commercial assets and late-stage protein and cell therapies at the developmental stage. 

Through its BioPartnering Solutions offerings, Bayer also aids third-party companies in carrying out clinical trials and launching products commercially.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.